Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04465955 · ClinicalTrials.gov registry record · Phase 2
A Study of NGM621 in Participants With Geographic Atrophy
A Phase 2 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT04465955 is a Phase 2 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 320 participants.
The verdict
NCT04465955, a Phase 2 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Interventions
- OTHER Sham Comparator
- BIOLOGICAL NGM621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2022-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04465955
The ClinicalTrials.gov registry entry for NCT04465955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT04465955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04465955 about?
NCT04465955 is a clinical study titled "A Study of NGM621 in Participants With Geographic Atrophy". This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
What is the current status of trial NCT04465955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2020-07-22. Estimated completion is 2022-08-16.
What interventions are being tested in trial NCT04465955?
The interventions under investigation include: Sham Comparator (OTHER), NGM621 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04465955?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.